Kim Tsuchimoto
Finanzdirektor/CFO bei MONOPAR THERAPEUTICS INC.
Vermögen: 30 837 $ am 31.05.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Patrice Rioux | M | 73 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 14 Jahre |
Christopher Starr | M | 71 |
Glyko, Inc.
Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | 18 Jahre |
Raymond Anderson | M | 82 | 12 Jahre | |
Brook Riggins | M | 58 | - | |
Chandler Robinson | M | 40 | 10 Jahre | |
Sara Isbell | F | - |
Mercaptor Discoveries, Inc.
Mercaptor Discoveries, Inc. Pharmaceuticals: MajorHealth Technology Mercaptor Discoveries, Inc. is a pharmaceutical company based in Novato, CA. The private company develops chemistry that gives CNS drugs potency without the commonly found toxicity. The company's approach flows from their discovery of chemistry existing within areas of the brain suffering neuropathology. Applying their discovery to neurology has illuminated a path forward for neurotherapeutics, delivering drugs capable of mounting a dynamic response to brain damage and dysfunction. Mercaptor Discoveries is a platform company with preclinical programs in neurology. The company's founding scientists discovered injury-activated molecules, called captons™ while at Raptor Pharmaceuticals, which they co-founded in 2006 and grew into a commercial company. Captons have reproducible proof-of-concept and efficacy as neuroprotectants and have the potential to prevent the progression of traumatic brain injury (TBI) and neurodegenerative diseases such as Alzheimer's disease, ALS, epilepsy, Parkinson's disease, MS, and stroke. The company was founded in 2016 by Todd Zankel, Sara Isbell, and Kim R. Tsuchimoto. Sara Isbell has been the CEO since 2016. | 8 Jahre |
Todd Zankel | M | - |
Mercaptor Discoveries, Inc.
Mercaptor Discoveries, Inc. Pharmaceuticals: MajorHealth Technology Mercaptor Discoveries, Inc. is a pharmaceutical company based in Novato, CA. The private company develops chemistry that gives CNS drugs potency without the commonly found toxicity. The company's approach flows from their discovery of chemistry existing within areas of the brain suffering neuropathology. Applying their discovery to neurology has illuminated a path forward for neurotherapeutics, delivering drugs capable of mounting a dynamic response to brain damage and dysfunction. Mercaptor Discoveries is a platform company with preclinical programs in neurology. The company's founding scientists discovered injury-activated molecules, called captons™ while at Raptor Pharmaceuticals, which they co-founded in 2006 and grew into a commercial company. Captons have reproducible proof-of-concept and efficacy as neuroprotectants and have the potential to prevent the progression of traumatic brain injury (TBI) and neurodegenerative diseases such as Alzheimer's disease, ALS, epilepsy, Parkinson's disease, MS, and stroke. The company was founded in 2016 by Todd Zankel, Sara Isbell, and Kim R. Tsuchimoto. Sara Isbell has been the CEO since 2016. | 8 Jahre |
Michael Brown | M | 67 | 10 Jahre | |
Arthur Klausner | M | 64 | 7 Jahre | |
George Davis | M | 53 | 20 Jahre | |
Elaine Heron | M | 76 | 22 Jahre | |
Brian Mueller | M | 50 | 22 Jahre | |
W. Mullally | M | 50 | 6 Jahre | |
Andrew Cittadine | M | 52 | 3 Jahre | |
Laura Kelly | F | - | 3 Jahre | |
Sheana Nieh | F | - |
Mercaptor Discoveries, Inc.
Mercaptor Discoveries, Inc. Pharmaceuticals: MajorHealth Technology Mercaptor Discoveries, Inc. is a pharmaceutical company based in Novato, CA. The private company develops chemistry that gives CNS drugs potency without the commonly found toxicity. The company's approach flows from their discovery of chemistry existing within areas of the brain suffering neuropathology. Applying their discovery to neurology has illuminated a path forward for neurotherapeutics, delivering drugs capable of mounting a dynamic response to brain damage and dysfunction. Mercaptor Discoveries is a platform company with preclinical programs in neurology. The company's founding scientists discovered injury-activated molecules, called captons™ while at Raptor Pharmaceuticals, which they co-founded in 2006 and grew into a commercial company. Captons have reproducible proof-of-concept and efficacy as neuroprotectants and have the potential to prevent the progression of traumatic brain injury (TBI) and neurodegenerative diseases such as Alzheimer's disease, ALS, epilepsy, Parkinson's disease, MS, and stroke. The company was founded in 2016 by Todd Zankel, Sara Isbell, and Kim R. Tsuchimoto. Sara Isbell has been the CEO since 2016. | 7 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jean-Jacques Bienaimé | M | 70 | 19 Jahre | |
Andrew Mazar | M | 62 | 8 Jahre | |
Todd C. Zankel | M | 60 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 12 Jahre |
Pierre LaPalme | M | 83 | 12 Jahre | |
Georgia Erbez | F | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 Jahre |
Grant W. Denison | M | - | - | |
Fredric D. Price | M | 78 | 4 Jahre | |
Joshua Grass | M | - | 14 Jahre | |
Louis C. Drapeau | M | 79 | 3 Jahre | |
Sandra Shpilberg | F | 48 | 9 Jahre | |
Vijay Samant | M | 77 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 6 Jahre |
Mark Wood | M | 57 | 9 Jahre | |
Alan J. Lewis | M | 78 | 15 Jahre | |
John Urquhart | M | - | - | |
Robert A. Heft | M | 69 | 3 Jahre | |
John Ditton | M | 60 | 2 Jahre | |
Steven Jungles | M | 58 | - | |
Amy Lea Waterhouse | F | - | - | |
Karl Cahill | M | 51 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | - |
Vimal Srivastava | M | 58 | 2 Jahre | |
Alejandro Dorenbaum | M | 64 | 7 Jahre | |
Dan Oppenheimer | M | - | 14 Jahre | |
Min MIn Qin | M | 66 | 7 Jahre | |
Matt Patterson | M | 52 | 6 Jahre | |
Robert Baffi | M | 68 | 20 Jahre | |
Craig Johnson | M | 62 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 1 Jahre |
Franz L. Cristiani | M | 83 | - | |
Stuart J. Swiedler | M | 68 | - | |
Erich Sager | M | 66 | 9 Jahre | |
Emil Kakkis | M | 63 | 11 Jahre | |
John C. Klock | M | 79 | - | |
Ansbert Gadicke | M | 66 | 4 Jahre | |
Joseph Klein | M | 62 | 5 Jahre | |
Suzanne Bruhn | M | 60 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 5 Jahre |
David Scott Geyer | M | 65 | 1 Jahre | |
Timothy Walbert | M | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 4 Jahre |
Gregg Lapointe | M | 65 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 Jahre |
Jeffrey Cooper | M | 68 | 9 Jahre | |
Gordon A. Landies | M | 67 |
International Microcomputer Software, Inc.
International Microcomputer Software, Inc. Packaged SoftwareTechnology Services International Microcomputer Software, Inc. develops software for productivity, utility, and digital image categories | - |
Octávio Costa | M | - | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 54 | 96,43% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Kim Tsuchimoto
- Persönliches Netzwerk